Recurred. How does this change my treatment choices, and are new targeted therapies using biomarkers (CD20, PD-L1)...

LymphomaOctober 15, 2025Navis AI

Ask Navis about your situation

This answer is general. Get one about your specific case. No signup, answered right here.

or Upload your records for answers about your actual case

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Sources & medical oversight

Grounded in NCCN Guidelines for Patients (Lymphomas) — the same guidelines oncologists use.
Built by OpenCancer’s team of physician-scientists and cancer survivors.
Last updated October 15, 2025. Informational only — not a substitute for your oncology team.

Question asked:

My Lymphoma has recurred. How does this change my treatment choices, and are new targeted therapies using biomarkers (CD20, PD-L1) available?

According to the NCCN Guidelines for Relapsed/Refractory Lymphoma (2023), treatment options depend on several factors, including:

The specific type of lymphoma you have
Time since your previous treatment
Your overall health and ability to tolerate different therapies
Results of biomarker testing

The Leukemia & Lymphoma Society (LLS) highlights several targeted therapy options based on biomarkers:

For CD20-positive lymphomas: newer anti-CD20 antibodies like obinutuzumab
For patients with positive PD-L1 expression: checkpoint inhibitors like pembrolizumab
CAR T-cell therapy for certain types of relapsed lymphomas

ASCO Guidelines (2023) recommend comprehensive molecular testing at relapse, as this can identify additional treatment options that may not have been available during your initial treatment. They specifically emphasize:

Biomarker testing should be repeated at relapse
Clinical trial participation should be considered
Treatment selection should be personalized based on molecular features

Important note: The specific treatment recommendations will depend on your exact lymphoma type, biomarker status, and other individual factors. It's essential to discuss these options with your oncologist who can review your specific case and make appropriate recommendations.

Would you like me to provide more specific information about any particular treatment approach or biomarker testing?

Ask Navis about your case

That answer is general. Ask about your specific situation. No signup, answered right here.

or Upload your records for answers about your actual case

Facing this with someone you love?

Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.

Start a care circle →